Double-blind, placebo-controlled randomized trial with adalimumab for treatment of juvenile onset ankylosing spondylitis (JoAS): significant short term improvement

Table 4 Serious adverse events

Adalimumab	Placebo
Appendicitis^1,4	Gastritis^2,4
Tendonitis^2,4
Sequence Adalimumab-Adalimumab	Sequence Placebo- Adalimumab
Pain^2,4	Colitis^3,4
Vertigo^3,4	Pyelonephritis^1,4

¹Judged as possibly related; ²Judged as not related; ³Judged as probably not related; ⁴Outcome: recovered completely. There were no events of malignancy, demyelinating disorders or deaths.

ISSN: 1478-6362